Trials / Conditions / Pseudomonas Aeruginosa Infection

Pseudomonas Aeruginosa Infection

15 registered clinical trials studyying Pseudomonas Aeruginosa Infection — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia NCT07492771	MicrobiotiX Co., Ltd	Phase 1
Not Yet Recruiting	Early Optimization of Ceftazidime Regimen in Critical Care NCT07085624	Centre Hospitalier Universitaire de Saint Etienne	N/A
Not Yet Recruiting	Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Ima NCT06986512	The First Affiliated Hospital with Nanjing Medical University	—
Completed	Development and Validation of (Bio)Sensors for the Identification of Pathogens NCT06548841	University of Bologna	—
Recruiting	Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals NCT06417593	Sohag University	—
Unknown	Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® NCT06319235	MB PHARMA s.r.o.	Phase 1 / Phase 2
Completed	Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis NCT06093191	Jin-Fu Xu	Phase 4
Terminated	Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients W NCT04673175	Weill Medical College of Cornell University	Phase 4
Completed	Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers NCT04803708	Technophage, SA	Phase 1 / Phase 2
Completed	Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients NCT02421120	Joseph L. Kuti, PharmD	Phase 4
Completed	Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 NCT01563263	Valneva Austria GmbH	Phase 2 / Phase 3
Completed	Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections NCT01315678	Insmed Incorporated	Phase 3
Completed	Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children NCT01429259	Joseph Kuti	Phase 4
Completed	Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa NCT01577368	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Phase 3
No Longer Available	Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bac NCT04636554	Adaptive Phage Therapeutics, Inc.	—